Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, ACC

MeaTech 3D Reports 2021 Financial Results and Provides Business Update


REHOVOT, Israel, March 24, 2022 /PRNewswire/ -- MeaTech 3D Ltd. (Nasdaq: MITC) ("MeaTech") announced today its financial results for 2021. The company is also providing an update to investors on recent business developments. MeaTech is an international deep-tech food company at the forefront of the cultured meat industry. The company is using science and technology to develop high-quality delicious and nutritious real meat products that are cell-based, slaughter free and safer than farm-raised meat.

 

MeaTech Logo

 


2021
Financial Results Summary

Arik Kaufman, MeaTech's Chief Executive Officer: "2021 marked a major turning point for MeaTech as we continue our quest to be positioned as the leaders in the cultured meat space. With our acquisition of Peace of Meat, our Belgian subsidiary, and the establishment of MeaTech Europe, we created a broad base of business with an infrastructure for offering cultured fat biomass as an ingredient to improve the taste and texture of alternative meat products. Throughout last year and into the beginning of this year, we made groundbreaking progress with our technological capabilities, which culminated in the world's largest ever 3D-printed cultivated steak and promising results with our muscle stem cell differentiation. Looking ahead, we will be expanding the company's operations. A memorandum of understanding has been signed for the establishment of a pilot plant in Belgium to accelerate the production of cultured chicken fat, and we are also, in the process of expanding to the US to advance our cellular technology."

Business highlights and developments during 2021 and to date:

Conference call details

The company will host a conference call today at 8:30 am (EDT). Management will be available to answer questions after providing a business update and presenting the results. To participate, please call one of the following telephone numbers a few minutes before the start of the call:

US:                                         1-888-281-1167                 8:30 am (Eastern Time)

Israel:                                      03-918-0609                     2:30 pm (Israel Time)

International:                          +972-3-918-0609

A live webcast of the conference call can be accessed on the MeaTech website at: 
https://meatech3d.com/events-presentations/

About MeaTech 3D

MeaTech is an international deep-tech food company at the forefront of the cultured meat revolution. The company initiated activities in 2019 and is listed on the Nasdaq Capital Market under the ticker "MITC". MeaTech maintains facilities in Rehovot, Israel and Antwerp, Belgium and is in the process of expanding activities to California, USA. The company believes cultivated meat technologies hold significant potential to improve meat production, simplify the meat supply chain, and offer consumers a range of new product offerings.  

MeaTech aims to provide an alternative to industrialized animal farming that dramatically reduces carbon footprint, minimizes water and land usage, and prevents the slaughtering of animals. By adopting a modular factory design, MeaTech will be able to offer a sustainable solution for producing a variety of beef, chicken and pork products, both as raw materials and whole cuts. The company will also provide meat manufacturers and retail businesses with production equipment.   

For more information, please visit: https://meatech3d.com

Forward-Looking Statements

This press release contains forward-looking statements concerning MeaTech's business, operations and financial performance and condition as well as plans, objectives, and expectations for MeaTech's business operations and financial performance and condition. Any statements that are not historical facts may be deemed to be forward-looking statements. Forward-looking statements reflect MeaTech's current views with respect to future events and are based on assumptions and subject to known and unknown risks and uncertainties, which change over time, and other factors that may cause MeaTech's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and are typically identified with words such as "may," "could," "should," "will," "would," "believe," "anticipate," "estimate," "expect," "aim," "intend," "plan" or words or phases of similar meaning and include, without limitation, MeaTech's expectations regarding the success of its cultured meat manufacturing technologies it is developing, which will require significant additional work before MeaTech can potentially launch commercial sales; MeaTech's research and development activities associated with technologies for cultured meat manufacturing, including three-dimensional meat production, which involves a lengthy and complex process; MeaTech's ability to obtain and enforce its intellectual property rights and to operate its business without infringing, misappropriating, or otherwise violating the intellectual property rights and proprietary technology of third parties; and other risks and uncertainties, including those identified in MeaTech's Annual Report on Form 20-F for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission on March 24, 2022. New risks and uncertainties may emerge from time to time, and it is not possible for MeaTech to predict their occurrence or how they will affect MeaTech. If one or more of the factors affecting MeaTech's forward-looking information and statements proves incorrect, then MeaTech's actual results, performance or achievements could differ materially from those expressed in, or implied by, forward-looking information and statements contained in this press release. Therefore, MeaTech cautions you not to place undue reliance on its forward-looking information and statements. MeaTech disclaims any duty to revise or update the forward-looking statements, whether written or oral, to reflect actual results or changes in the factors affecting the forward-looking statements, except as specifically required by law.

MeaTech Press Contact:
Maissa Dauriac 
Rainier Communications
[email protected]

MeaTech Investor Contacts:

Joseph Green
Edison Group 
[email protected]    

Ehud Helft
Edison Israel 
[email protected]

Logo - https://mma.prnewswire.com/media/1753830/MeaTech_Logo.jpg

SOURCE MeaTech 3D Ltd.


These press releases may also interest you

at 07:00
J2 Ventures, a deep tech venture capital fund focused on new technologies that are critical for both the private sector and national security interests of the U.S and its allies, has raised $150 million for its new Argonne Fund. The oversubscribed...

at 07:00
Intellias, a global software engineering and consulting company, introduces a new partnership with ZENRIN, a leading Japan map data provider, to develop cutting-edge digital maps enriched with Japan map data tailored for modern car navigation...

at 07:00
The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, will participate in an announcement about support for the manufacturing and commercialization of semiconductors. By focusing on support for this industry, we're...

at 06:33
The world of digital advancements is experiencing a phenomenal level of explosive growth, and Salesforce, a leading customer relationship management (CRM) platform, has witnessed staggering popularity and an exponential level of advancement in India....

at 06:30
CGI today announced the acquisition of Celero's credit union business serving clients across Canada, consisting of master services agreements that span managed services, core banking, digital banking and related IT services. The strategic...

at 06:30
The global microscopy market is poised for significant growth, expected to reach USD 10.6 billion by 2029 from USD 8.1 billion in 2024, growing at a CAGR of 5.4%. Key drivers include rising cases of chronic diseases necessitating effective...



News published on and distributed by: